To investigate the long-term effects of the inhaled anticholinergic bronchodilator, oxitropium bromide (OTB), on lung function, exercise capacity, and dyspnea in patients with chronic obstructive pulmonary disease (COPD), spirometry and symptom-limited exercise testing before and 1, 6, and 12 months after the regular use of OTB (600 |ig/day) were performed in 12 patients with the use of OTB(mean age 69.9+3.1 years; FEVx/FVC53.3+1.6%) as well as in 12 control patients who were not treated with OTB(Mean age 68.8+2.8 years; FEVx/FVC52.6±1.9%). The dyspnea was evaluated by the slope of the regression line between Borg scale and oxygen uptake (Vo2) during exercise (Borg scale slope: BSS). At 1, 6, and 12 months after the start of OTB, the forced expiratory volume in one second (FEVX) and the exercise capacity (maximal Vo2) were greater than the pretreatment values and the dyspnea index (BSS) was significantly improved compared with the pretreatment value, while these parameters slightly worsened in the control patients over one year. In conclusion, the chronic use of an inhaled anticholinergic bronchodilator may provide beneficial improvements in expiratory flow rate, exercise performance, and dyspnea in mild to moderate COPDpatients over one year. (Internal Medicine 35: 772-778, 1996) 
Introduction
Owing to the increase in cigarette use and the burgeoning population of elderly, chronic obstructive pulmonary disease (COPD)has become a major health problem worldwide. COPD is a slow but progressive disease, the treatment of which focuses on a significant bronchodilating effect for maintaining lung function, and achievement of an acceptable quality of life. In addition, it has been reported that regular administration of a bronchodilator to COPDpatients with hyperresponsive airwaysappears to mitigate the accelerated rate of decline of lung function ( 1 ) . Long-term bronchodilator administration seems to be a reasonable intervention for slowing the development of clinical COPDin smokers (2) .
Inhaled anticholinergic drug is one of the major bronchodilators for use in patients with COPD (3) . Several lines of evidence indicate that the anticholinergic drug may improve air flow limitation in patients with COPDmore effectively and over a longer period of time than does an inhaled (3-agonist (4-7) , since the pathogenesis of COPDis associated with higher cholinergic airway tone (8). Because anticholinergic bronchodilators are effective and particularly safe in patients with COPD, the inhalational drugs are now often recommended as first-line agents in the place of (32-adrenergic agonists (8, 9) . Although acute responses to anticholinergic agents in COPD patients have been extensively reported ( 1 0-1 9), limited information is available regarding the long-term effects of anticholinergics on air flow limitation and exercise performance in COPDpatients. In this study, the long-term effects of the anticholinergic drug, oxitropium bromide (OTB), on lung function, exercise performance, and exertional dyspnea in mild to moderate COPDpatients were investigated in mild to moderate COPDpatients.
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Methods
Patien ts
Twenty-four male patients with mild to moderate COPD were enrolled in this study. Our population was defined by history and the usual supporting radiologic and pulmonary function criteria ( 1 8, 19) . All patients were ex-smokers who had quit smoking for at least one year. No patients had a forced expiratory volume in one second (FEVj) that was greater than 60%of the volume predicted, and no patient had more than 15%reversibility on a (3-adrenergic inhalation test. In addition, no patients had a diffusing capacity of the lung for CO (Deo) of more than 60% of that predicted. Predicted values for vital capacity and Deowere recalculated using the equation of Baldwin et al (20) and Burrows et al (21) , respectively. Prior to the beginning of this study, all patients gave informed consent.
Trea tmen t
Fourteen of the 28 patients were randomly selected for the OTBgroup, and the other 14 assigned to the control group. Control-group patients did not receive any specific drug for treatment ofCOPDand were followed up for a year. In the OTB group, patients were withheld from all treatment for 4 weeks prior to the study. After being introduced to the study, patients in the treatment group were started on inhaled OTB200 \ig (two puffs) three times daily for one year. At 8-9 am, 2-3 pm, and 8-9 pm, the OTBwas administered in two puffs from identical metered-dose inhalers. The use of other drugs was avoided during the one-year treatment of OTB.
Study design
In the OTBtreated patients, pulmonary function test (PFT) at rest and exercise testing were performedbefore the beginning ofOTBtreatment as well as at one, six, and twelve months after treatment. In control patients, PFTat rest and exercise testing were performed under the same conditions and time schedule. On the test day, each study started around 1 0 am, approximately 1 or 2 hours after the inhalation of OTB. Spirometric indices were obtained for each patient from the three best maximal flow-volume curves using a dry-sealed-type box spirometer Fukuda Sangyo, Japan) . Forced vital capacity (FVC), FEVj, and peak expiratory flow rate (PEFR) were measured.
About 10-15 minutes after the spirometric procedures, progressive incremental exercise testing was performed to a symptom-limited maximumon a bicycle ergometer (Collins Corp., Braintree, MA). After 1 minute of unloading cycling, the work load was increased by 10 watt each minute until patient failure. All patients stopped the exercise test mainly due to dyspnea.
pneumotachometer -computer (PC-9801 , NEC Corp, Japan) system (WLCS-5100, Westron Corp). Prior to each test, the spirometer was calibrated with a 2-L calibration syringe, and the massspectrometer wascalibrated against gas mixtures of known concentrations (O2 20.9%, Ar 9.5%, CO2 5.00%, C2H2 0.650%, N2 balance) (22). Arterial oxygen saturation (SaO2) was continuously monitored before, during and after the exercise using a pulse oximeter (502-P, Criticare System Inc.). Rest SaO2 was determined from the stable SaO2 in the resting ventilation immediately before exercise. Nadir SaO2 was determined as the minimumvalue which was observed during the exercise test.
Assessment of dyspnea during exercise Dyspneaduring exercise was evaluated using the index on the linear relationship between the Borg scale (BS) (23) and Vo2 as described elsewhere (24). Briefly, we assessed the sensation of difficult breathing in the patients using BS in each load of the exercise testing. In all patients, there was a significant positive correlation between the dyspnea expressed on BS and Vo2 during exercise. From this correlation, we determined Borg Scale Slope (BSS) as the slope of the regression line (the slope of ABS/AVo2) and Threshold Load of Dyspnea (TLD) as the X intercept of the regression for the quantitative assessment of dyspnea (24).
Statistical analysis
Analysis of variance (ANOVA) with Fisher's protected least significant difference method was used for comparing the data in the same group. Data were analyzed with Student's unpaired t test between the OTBtreated and the untreated group; the analyses were performed by Stat View 4.0 (Abacus Concepts, Inc.). p<0.05 was considered statistically significant. Data were presented as mean±SE.
Results
Twelve offourteen patients in the OTBgroup and twelve of fourteen patients in the control group completed the entire study and were then available for assessment in this study. The remaining 2 patients in both groups were dropped from the study; in the OTBgroup, one patient was admitted to the hospital for bacterial pneumonia, and the other could not adhere to regular use ofOTBinhalation despite meticulous instruction; in the control group, two subjects experienced acute exacerbation due to a viral/bacterial infection. The mean (+SE) age of patients with COPDwas 69.9±3.1 years in the OTB group, and 68.8+2.8 years in the control group. The demographic and anthropometric data of the patients are given in Table 1 1996) no difference in the maximal oxygen uptake between the OTB and control groups (Fig. 2) . The exercise capacity was increased by the inhalation of OTBand the increase in the maximal Vo2 lasted over time (Fig. 2) . Other results ofventilatory parameters during exercise are presented in Table 3 . One month after starting the use of OTB, the maximal ventilation and pulse rate were increased. However, the effects of the OTBadministration on ventilation and pulse rate were not obvious 6 months after treatment. At the peak of;exercise, a slightly decreased respiratory frequency and slightly increased minute ventilation were observed in the OTBtreated patients, but these increments were not significant. The ventilatory equivalency for oxygen uptake (Ve/Vo2) during exercise was small, but significantly less after OTBtreatment than before. Throughout the study, the rest SaO2 was not different between the treated and untreated group. Nadir SaO2 during exercise was slightly improved after the use of OTB, but did not reach a significant level ( the magnitude of its decrease remained constant up to 12 months after the start of OTBtreatment (Fig. 3) . In the control patients, there was no change in BSS over the year (Fig. 3) .
Discussion
Oxitropium bromide (OTB) is a newly introduced anticholinergic drug which has been used for COPDpatients in several countries (4, (14) (15) (16) (17) (18) (19) Presented as mean±SE. *p<0.05, compared with the same value before the treatment; VE: minute ventilation, Rf: respiratory frequency, Vo2: oxygen uptake, PR: pulse rate, AVe/AVo2: ventilatory equivalency for oxygen uptake, Nadir Sao2: the minimum value of Sao2 in the exercise testing. Abbreviations as in Table 2 .
Internal Medicine Vol. 35, No. 10 (October 1996) Presented as mean±SE. OTB, patients treated with oxitropium bromide (OTB); CTRL,the untreated patients. *p<0.05, comparedwith the same value before the treatment; before; prior to introducing the treatment with OTB. 1, 6, 12 months; 1, 6, 12 months after introducing the treatment with OTB; BSmax,the maximal score ofBorg scale (BS) during exercise; BSS, Borg scale slope as determined by the slope of the regression line between BS and oxygen uptake (Vo2) during exercise; TLD, threshold load of dyspnea as determined by the X intercept of the regression line between BS and oxygen uptake (Vo2) Figure 3 . The mean value of dyspnea index during exercise before and over a year of study in patients with COPD.Dyspnea index was determined as the slope of the regression line between BS and Vo2 during exercise (Borg scale slope; BSS (BS///min)).
Open circles, untreated patients; Closed circles, OTB treated patients. *p<0.05 compared with the value ofOTB treated patients before the treatment. Data are presented as mean±SE.
Although (32-adrenergic inhalational agents are known to exhibit considerable bronchodilating effects on COPD, it has been speculated that the tachyphylaxis, desensitization, and downregulation of adrenoreceptor function are caused by regular use of the agents. In contrast, our observation mayindicate that long-term, regular use of OTBproduces a constant level of bronchodilation without obvious tachyphylaxis and desensitization. Because COPDis a life-long disease, anticholinergic inhalation may be suitable for achieving significant bronchodilation and improving dyspnea during exercise through regular use without untoward effects. Because dyspnea on exertion is one of the major symptoms of COPD,often sufficient to limit a patient's physical activity, its reduction during exercise and the subsequent increase in exercise performance may allow OTBuse to enhance a subset of the patient's quality of life. At present, bronchodilators, including beta-agonists and anticholinergics, oxygen therapy, mucoactive drugs, and antibiotics are effective for COPD (3, 10) . However, because
COPDincreases in frequency with age, it is often a disease of the elderly (25, 26) , and a complicated treatment regimen may not be appropriate. Further, it has been suggested that compliance with bronchodilators remains a problem in COPDpatients partly due to the bronchodilators' side effects (27, 28) . Because anticholinergic inhalation is safe and effective, it may be a candidate therapy for COPDpatients. Although it has been suggested that the possible long-term effects of a bronchodilator may be detected by use of an adrenergic bronchodilator ( 1), recent data mayindicate that use of a maximaldose ofipratropium bromide is better in terms of lung function and secondary efficacy variables (including dyspnea and lower respiratory events), than use of an adrenergic drug for 3 months (29). Thus, further comparativestudies of the long-termeffects on lung function and symptomsof the other bronchodilators, including (3-agonists and corticosteroids, may be important for determining the efficacy of anticholinergic inhalation for COPDpatients (1, 30 ).
In the current study, the improvementin dyspnea was determined by the decrease in BSS (the slope of ABS/AVo2), but not by changes in the intercept of the regression line (TLD). Because the former index may reflect the dyspnea sensitivity to exercise and the latter variable mayindicate the dyspnea onset with exercise, the reduction of dyspnea during exercise following treatment with OTBmainly resulted from the blunted perception of dyspnea during exercise. However, the mecha-Effect of Anticholinergic Inhalation on COPD nism of the improvement of dyspnea is not clearly determined by this study, since the dyspnea sensation includes not one but numerous complicated mechanisms consisting of chemoreceptors, the higher central nervous system, peripheral mechanoreceptors in the respiratory muscles, chest wall, and upper airways, and the psychophysiologic state in patients with COPD (3 1-33) . One of the possible explanations for the reduction ofdyspnea during exercise following OTBtreatment is that the improvement in ventilatory efficiency (lowered Ve/Vo2) maycontribute to reducing the increase in oxygen demand during exercise. Moreover, the improvement in air flow limitation maybe related to the improved elastic recoil and the decreased functional residual capacity, which may increase the diaphragm fiber length allowing the diaphragm to generate morepressure for a given neural output, and subsequently improve breathlessness. However, it remains unclear why the TLDis unaffected by OTB inhalation; further basic physiologic studies appear necessary to clarify the mechanismof dyspnea in this regard.
In patients with COPD,the improvements in spirometric indices by the administration of anticholinergic drugs have been extensively investigated (4-6, 1 1-15 The major limitation of the present study is the small sample size of both groups. However, the acute effects of the inhaled OTB on pulmonary function and the sensation of dyspnea during exercise in COPDpatients have been reported by several investigators (12, 13, 16, 17) , and a similarmagnitude of effects on lung function and dyspnea was replicated in this study, implying that the results of the current study maybe acceptable for assuming the long-term effects of OTBin COPDpatients. Weconclude that inhaled oxitropium bromide may produce significant improvements in both dyspnea sensation and exercise performance of patients with COPD in chronic as well as acute cases.
